Mild cognitive impairment can be detected by multiple assessments in a single day
Mild cognitive impairment can be detected by multiple assessments in a single day
复制标题
DOI：
10.1212/wnl.59.7.1042
复制
发表时间：
2002-10-08
期刊：
影响因子：
9.9
通讯作者：
McStephen, M
中科院分区：
文献类型：
--
作者：
Darby, D;Maruff, P;McStephen, M
背景：在许多情况下，在AD之前对轻度认知损害(MCI)进行可靠的检测，对于确定新出现的治疗方法的疗效是重要的。MCI的业务定义目前并不准确，将通过客观标准加以改进。从MCI到AD的过渡过程中固有的是认知能力下降，这可以通过几年的多项评估来检测到。目的：确定同一天的多项评估是否也可以区分研究充分的受试者和正常对照受试者。方法：这项研究使用了一种新型的15到18分钟的计算机化认知电池，专为频繁连续使用而设计，在3小时内给药4次。受试者是纵向健康老龄化研究的参与者(20名MCI患者，40名年龄、性别和教育程度匹配的对照受试者)。结果：MCI组在准确度和反应时任务上的重复显著降低了学习成绩。判别函数分析对95%的受试者和80%的MCI患者进行了正确的分类。结论：采用标准化的、可重复的认知测量的多重评估是一种在单次测试中可靠地区分早期MCI患者的有前景的方法，值得进一步研究，以完善MCI治疗药物试验中的患者选择。
Background: Reliable detection of mild cognitive impairment (MCI), in many cases preceding AD, is important in determining the efficacy of emerging treatments. The operational definition of MCI is currently imprecise and would be improved by objective criteria. Inherent in the transition from MCI to AD is cognitive decline, which can be detected using multiple assessments over several years. Objective: To determine whether multiple assessments on the same day could also differentiate well-studied subjects with very mild MCI from normal control subjects. Methods: This study utilized a novel 15- to 18-minute computerized cognitive battery designed for frequent serial use, administered four times within 3 hours. Subjects were participants in a longitudinal healthy aging study (20 with MCI, 40 control subjects matched for age, gender, and education). Results: The MCI group showed significantly attenuated learning performance with repetition on accuracy and reaction time tasks. Discriminant function analysis correctly classified 95% of subjects and 80% of those with MCI. Conclusions: Multiple assessments with standardized, repeatable cognitive measures is a promising method for reliably differentiating patients with early MCI in a single test session and deserves further study for refining patient selection in trials of therapeutic agents for MCI.